Inter- and intra-observational variability in immunohistochemistry: A multicentre analysis of diffuse large B-cell lymphoma staining

Histopathology

Volumn 61, Issue 1, 2012, Pages 18-25

  Lawrie, Charles H ^a,b,c   Ballabio, Erica ^b,c   Soilleux, Elizabeth ^b,c,d   Sington, James ^e   Hatton, Christian S R ^d   Dirnhofer, Stephan ^f   Tzankov, Alexandar ^f  

^a BIODONOSTIA HEALTH RESEARCH INSTITUTE   (Spain)

^b BASQUE FOUNDATION FOR SCIENCE   (Spain)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^e NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

^f UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Bcl 6; CD10; Diffuse large B cell lymphoma; FOXP1; GCET1; Immunohistochemistry; Lymphoma; MUM1

Indexed keywords

COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; INTERFERON REGULATORY FACTOR 4; PROTEIN BCL 6; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FOXP1; TRANSCRIPTION FACTOR GCET1; UNCLASSIFIED DRUG;

ARTICLE; CRONBACH ALPHA COEFFICIENT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; STAINING; TISSUE MICROARRAY;

HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOMA, LARGE B-CELL, DIFFUSE; OBSERVER VARIATION; REPRODUCIBILITY OF RESULTS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84862875240     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2012.04179.x     Document Type: Article

References (19)

1. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. REporting recommendations for tumour MARKer prognostic studies (REMARK). Eur. J. Cancer 2005; 41; 1690-1696.
2. Kyzas PA, Denaxa-Kyza D, Ioannidis JP. Almost all articles on cancer prognostic markers report statistically significant results. Eur. J. Cancer 2007; 43; 2559-2579.
3. Riley RD, Sauerbrei W, Altman DG. Prognostic markers in cancer: the evolution of evidence from single studies to meta-analysis, and beyond. Br. J. Cancer 2009; 100; 1219-1229.
4. Hans CP, Weisenburger DD, Greiner TC et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103; 275-282.
5. Choi WW, Weisenburger DD, Greiner TC et al. A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin. Cancer Res. 2009; 15; 5494-5502.
6. Cronbach L. Coefficient alpha and the internal structure of tests. Psychometrika 1951; 16; 297-334.
7. Bland JM, Altman DG. Cronbach's alpha. BMJ 1997; 314; 572.
8. Tzankov A, Zlobec I, Went P, Robl H, Hoeller S, Dirnhofer S. Prognostic immunophenotypic biomarker studies in diffuse large B cell lymphoma with special emphasis on rational determination of cut-off scores. Leuk. Lymphoma 2010; 51; 199-212.
9. Quackenbush J. Microarray analysis and tumor classification. N. Engl. J. Med. 2006; 354; 2463-2472.
10. Coiffier B. Diffuse large cell lymphoma. Curr. Opin. Oncol. 2001; 13; 325-334.
11. Lenz G, Staudt LM. Aggressive lymphomas. N. Engl. J. Med. 2010; 362; 1417-1429.
12. Alizadeh AA, Eisen MB, Davis RE et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403; 503-511.
13. Iqbal J, Liu Z, Deffenbacher K, Chan WC. Gene expression profiling in lymphoma diagnosis and management. Best Pract. Res. 2009; 22; 191-210.
14. Nyman H, Adde M, Karjalainen-Lindsberg ML et al. Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy. Blood 2007; 109; 4930-4935.
15. Tzankov A, Went P, Dirnhofer S. Prognostic significance of in situ phenotypic marker expression in diffuse large B-cell lymphomas. Biomark Insights 2007; 2; 403-417.
16. de Jong D, Rosenwald A, Chhanabhai M et al. Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications-a study from the Lunenburg Lymphoma Biomarker Consortium. J. Clin. Oncol. 2007; 25; 805-812.
17. de Jong D, Xie W, Rosenwald A et al. Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications (a study from the Lunenburg Lymphoma Biomarker Consortium). J. Clin. Pathol. 2009; 62; 128-138.
18. Zu Y, Steinberg SM, Campo E et al. Validation of tissue microarray immunohistochemistry staining and interpretation in diffuse large B-cell lymphoma. Leuk. Lymphoma 2005; 46; 693-701.
19. Meyer PN, Fu K, Greiner TC et al. Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab. J. Clin. Oncol. 2011; 29; 200-207.